Hendrick Simon Schaaf

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/361501/publications.pdf

Version: 2024-02-01

174 papers	10,475 citations	31976 53 h-index	36028 97 g-index
176 all docs	176 docs citations	176 times ranked	7348 citing authors

#	Article	IF	Citations
1	Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children. Clinical Infectious Diseases, 2022, 74, 1372-1381.	5.8	13
2	The Diagnostic Accuracy of Chest Radiographic Features for Pediatric Intrathoracic Tuberculosis. Clinical Infectious Diseases, 2022, 75, 1014-1021.	5.8	6
3	Priority Activities in Child and Adolescent Tuberculosis to Close the Policy-Practice Gap in Low- and Middle-Income Countries. Pathogens, 2022, 11, 196.	2.8	11
4	Tuberculous Meningitis in Children: A Forgotten Public Health Emergency. Frontiers in Neurology, 2022, 13, 751133.	2.4	3
5	Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. International Journal of Infectious Diseases, 2022, 124, S90-S103.	3.3	18
6	Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis. Clinical Infectious Diseases, 2022, 75, 1772-1780.	5.8	8
7	Treatment of Rifampicin-Resistant Tuberculosis Disease and Infection in Children: Key Updates, Challenges and Opportunities. Pathogens, 2022, 11, 381.	2.8	13
8	Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial. Antimicrobial Agents and Chemotherapy, 2022, 66, e0214421.	3.2	8
9	Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. Lancet Infectious Diseases, The, 2022, 22, 1042-1051.	9.1	28
10	PositiveMycobacterium tuberculosisGastric Lavage Cultures from Asymptomatic Children With Normal Chest Radiography. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 502-508.	1.3	2
11	Multidrug-resistant tuberculosis in children and adolescents: current strategies for prevention and treatment. Expert Review of Respiratory Medicine, 2021, 15, 221-237.	2.5	19
12	The Impact of the Evolving Human Immunodeficiency Virus Response on the Epidemiology of Tuberculosis in South African Children and Adolescents. Clinical Infectious Diseases, 2021, 73, e967-e975.	5.8	5
13	Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. Pulmonology, 2021, 27, 248-256.	2.1	18
14	Childhood Cancers Misdiagnosed as Tuberculosis in a High Tuberculosis Burden Setting. Pediatric Infectious Disease Journal, 2021, 40, 1076-1080.	2.0	6
15	Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial. Journal of Antimicrobial Chemotherapy, 2021, 76, 3237-3246.	3.0	26
16	Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis. Frontiers in Pharmacology, 2021, 12, 722204.	3.5	3
17	Management of tuberculous meningitis in children. Paediatrics and International Child Health, 2021, 41, 231-236.	1.0	6
18	Abdominal Tuberculosis in Children: Challenges, Uncertainty, and Confusion. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 218-227.	1.3	25

#	Article	IF	Citations
19	Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	7
20	Fine Needle Aspiration Biopsy of Peripheral Lymph Nodes in Children: Practical Experience in a Tertiary Hospital. Journal of Tropical Pediatrics, 2020, 67, .	1.5	2
21	Abdominal Involvement in Children With Bacteriologically Confirmed Tuberculosis. Pediatric Infectious Disease Journal, 2020, 39, 914-919.	2.0	6
22	Adverse Events Associated With New Injectable-Free Multidrug-Resistant Tuberculosis Drug Regimens. Archivos De Bronconeumologia, 2020, 56, 823-825.	0.8	0
23	The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet, The, 2020, 395, 973-984.	13.7	160
24	Trends in Drug Resistance in Childhood Tuberculosis in Cape Town, South Africa. Pediatric Infectious Disease Journal, 2020, 39, 604-608.	2.0	6
25	Tuberculosis treatment in children: The changing landscape. Paediatric Respiratory Reviews, 2020, 36, 33-43.	1.8	12
26	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. International Journal of Infectious Diseases, 2020, 92, S15-S25.	3.3	126
27	Adverse Events Associated With New Injectable-Free Multidrug-Resistant Tuberculosis Drug Regimens. Archivos De Bronconeumologia, 2020, 56, 823-825.	0.8	1
28	The Role of Xpert MTB/RIF Ultra in Diagnosing Pulmonary Tuberculosis in Children. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1464-1465.	5.6	8
29	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respiratory Medicine,the, 2019, 7, 820-826.	10.7	92
30	Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	14
31	Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies. PLoS Medicine, 2019, 16, e1002789.	8.4	41
32	Acceptability of a Novel Levofloxacin Dispersible Tablet Formulation in Young Children Exposed to Multidrug-resistant Tuberculosis. Pediatric Infectious Disease Journal, 2019, 38, 608-610.	2.0	8
33	Specimen Pooling as a Diagnostic Strategy for Microbiologic Confirmation in Children with Intrathoracic Tuberculosis. Pediatric Infectious Disease Journal, 2019, 38, e128-e131.	2.0	16
34	Treatment Outcomes in Global Systematic Review and Patient Meta-Analysis of Children with Extensively Drug-Resistant Tuberculosis. Emerging Infectious Diseases, 2019, 25, 441-450.	4.3	16
35	Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2019, 200, e93-e142.	5.6	282
36	Culture-confirmed Tuberculosis in South African Infants Younger Than 3 Months of Age. Pediatric Infectious Disease Journal, 2019, 38, 351-354.	2.0	4

#	Article	IF	Citations
37	Diagnosis and Management of Multidrug-Resistant Tuberculosis in Children: A Practical Approach. Indian Journal of Pediatrics, 2019, 86, 717-724.	0.8	21
38	Adolescents and young adults: a neglected population group for tuberculosis surveillance. European Respiratory Journal, 2018, 51, 1800176.	6.7	16
39	Tuberculous Pericardial Effusions in Children. Journal of the Pediatric Infectious Diseases Society, 2018, 7, 346-349.	1.3	10
40	Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children. Expert Review of Clinical Pharmacology, 2018, 11, 233-244.	3.1	18
41	Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respiratory Medicine,the, 2018, 6, 265-275.	10.7	80
42	Effect of Coadministration of Lidocaine on the Pain and Pharmacokinetics of Intramuscular Amikacin in Children With Multidrug-Resistant Tuberculosis: A Randomized Crossover Trial. Pediatric Infectious Disease Journal, 2018, 37, 1199-1203.	2.0	7
43	Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	37
44	Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	16
45	Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP). Trials, 2018, 19, 693.	1.6	36
46	Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis. Lancet Respiratory Medicine,the, 2018, 6, 662-664.	10.7	19
47	Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant Tuberculosis. Clinical Infectious Diseases, 2018, 67, 1777-1780.	5.8	24
48	Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Medicine, 2018, 15, e1002591.	8.4	96
49	Complementary surveillance strategies are needed to better characterise the epidemiology, care pathways and treatment outcomes of tuberculosis in children. BMC Public Health, 2018, 18, 397.	2.9	14
50	Xpert MTB/RIF on Stool Is Useful for the Rapid Diagnosis of Tuberculosis in Young Children With Severe Pulmonary Disease. Pediatric Infectious Disease Journal, 2017, 36, 837-843.	2.0	56
51	Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis. Journal of Antimicrobial Chemotherapy, 2017, 72, 1848-1857.	3.0	4
52	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respiratory Medicine,the, 2017, 5, 291-360.	10.7	459
53	Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis. Expert Opinion on Pharmacotherapy, 2017, 18, 589-598.	1.8	12
54	New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1300-1310.	5.6	61

#	Article	IF	Citations
55	The impact of drug resistance on the risk of tuberculosis infection and disease in child household contacts: a cross sectional study. BMC Infectious Diseases, 2017, 17, 593.	2.9	13
56	Probable Levofloxacin-associated Secondary Intracranial Hypertension in a Child With Multidrug-resistant Tuberculosis. Pediatric Infectious Disease Journal, 2016, 35, 706-708.	2.0	20
57	Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis. Pneumonia (Nathan Qld), 2016, 8, 20.	6.1	16
58	Adverse effects of oral second-line antituberculosis drugs in children. Expert Opinion on Drug Safety, 2016, 15, 1369-1381.	2.4	29
59	Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clinical Infectious Diseases, 2016, 63, e147-e195.	5.8	916
60	The safety and tolerability of the second-line injectable antituberculosis drugs in children. Expert Opinion on Drug Safety, 2016, 15, 1491-1500.	2.4	13
61	Multidrug-Resistant Tuberculosis in Children: Recent Developments in Diagnosis, Treatment and Prevention. Current Pediatrics Reports, 2016, 4, 53-62.	4.0	4
62	Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clinical Infectious Diseases, 2016, 63, 853-867.	5.8	237
63	Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. European Respiratory Journal, 2016, 48, 938-943.	6.7	71
64	Update on multidrug-resistant tuberculosis in children. International Journal of Mycobacteriology, 2016, 5, S7.	0.6	0
65	Antituberculosis drugs in children. Clinical Pharmacology and Therapeutics, 2015, 98, 252-265.	4.7	21
66	Clinicoradiologic Response of Neurologic Tuberculous Mass Lesions in Children Treated With Thalidomide. Pediatric Infectious Disease Journal, 2015, 34, 214-218.	2.0	29
67	Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. Lancet Infectious Diseases, The, 2015, 15, 711-720.	9.1	66
68	Optimizing the Detection of Recent Tuberculosis Infection in Children in a High Tuberculosisâ€“HIV Burden Setting. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 820-830.	5.6	46
69	Pharmacokinetics and Safety of Moxifloxacin in Children With Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases, 2015, 60, 549-556.	5.8	62
70	Successful Treatment of a Child With Extensively Drug-Resistant Tuberculous Meningitis: Figure 1.. Journal of the Pediatric Infectious Diseases Society, 2015, 4, e41-e44.	1.3	6
71	Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2015, 59, 6073-6079.	3.2	17
72	ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. European Respiratory Journal, 2014, 44, 811-815.	6.7	96

#	Article	IF	Citations
73	Managing multidrug-resistant tuberculosis in children. Current Opinion in Infectious Diseases, 2014, 27, 211-219.	3.1	25
74	Short Intensified Treatment in Children with Drug-susceptible Tuberculous Meningitis. Pediatric Infectious Disease Journal, 2014, 33, 248-252.	2.0	91
75	Child health and tuberculosis. Lancet Respiratory Medicine,the, 2014, 2, 254-256.	10.7	15
76	High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax, 2014, 69, 458-464.	5.6	89
77	Linezolid for the treatment of drug-resistant tuberculosis in children: A review and recommendations. Tuberculosis, 2014, 94, 93-104.	1.9	51
78	Tuberculosis in Children. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a017855-a017855.	6.2	66
79	Assessing the impact of multidrug-resistant tuberculosis in children: an exploratory qualitative study. BMC Infectious Diseases, 2014, 14, 426.	2.9	34
80	The value of transcranial Doppler imaging in children with tuberculous meningitis. Child's Nervous System, 2014, 30, 1711-1716.	1.1	22
81	Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. Journal of Antimicrobial Chemotherapy, 2014, 69, 1339-1349.	3.0	53
82	Acquired Drug Resistance During Inadequate Therapy in A Young Child with Tuberculosis. Pediatric Infectious Disease Journal, 2014, 33, 883-885.	2.0	12
83	In Reply. Pediatric Infectious Disease Journal, 2014, 33, 993-994.	2.0	1
84	Toxicity and Tolerability of Fluoroquinolone-based Preventive Therapy for Childhood Contacts of Multidrug-resistant Tuberculosis. Pediatric Infectious Disease Journal, 2014, 33, 1098-1099.	2.0	5
85	A new paradigm for multidrug-resistant tuberculosis?. International Journal of Tuberculosis and Lung Disease, 2014, 18, 884-884.	1.2	1
86	In Reply. Pediatric Infectious Disease Journal, 2014, 33, 1205-1206.	2.0	1
87	Risk factors for infection and disease in child contacts of multidrug-resistant tuberculosis: a cross-sectional study. BMC Infectious Diseases, 2013, 13, 392.	2.9	25
88	Hearing loss in children treated for multidrug-resistant tuberculosis. Journal of Infection, 2013, 66, 320-329.	3.3	71
89	Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. European Respiratory Journal, 2013, 42, 169-179.	6.7	226
90	Retooling Existing Tuberculosis Drugs for Children. Clinical Infectious Diseases, 2013, 56, 167-168.	5.8	6

#	Article	IF	Citations
91	Consensus Statement on Research Definitions for Drug-Resistant Tuberculosis in Children. Journal of the Pediatric Infectious Diseases Society, 2013, 2, 100-109.	1.3	40
92	Preventive Therapy for Child Contacts of Multidrug-Resistant Tuberculosis: A Prospective Cohort Study. Clinical Infectious Diseases, 2013, 57, 1676-1684.	5.8	101
93	Detecting Tuberculosis Infection in HIV-infected Children. Pediatric Infectious Disease Journal, 2013, 32, e111-e118.	2.0	44
94	Isoniazid preventive therapy in HIV-infected and -uninfected children (0 - 14 years). South African Medical Journal, 2013, 103, 714.	0.6	9
95	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. PLoS Medicine, 2012, 9, e1001300.	8.4	430
96	Nutritional status and its response to treatment of children, with and without HIV infection, hospitalized for the management of tuberculosis. Paediatrics and International Child Health, 2012, 32, 74-81.	1.0	11
97	Hearing loss in patients on treatment for drug-resistant tuberculosis. European Respiratory Journal, 2012, 40, 1277-1286.	6.7	96
98	Culture-Confirmed Multidrug-Resistant Tuberculosis in Children: Clinical Features, Treatment, and Outcome. Clinical Infectious Diseases, 2012, 54, 157-166.	5.8	89
99	Multidrug-Resistant Tuberculosis of the Spine in Children--Characteristics from a High Burden Setting. Journal of Tropical Pediatrics, 2012, 58, 341-347.	1.5	13
100	Impact of Drug Resistance on Clinical Outcome in Children With Tuberculous Meningitis. Pediatric Infectious Disease Journal, 2012, 31, 711-716.	2.0	47
101	A Proposed Comprehensive Classification of Tuberculosis Disease Severity in Children. Pediatric Infectious Disease Journal, 2012, 31, 347-352.	2.0	85
102	Discordant Drug Susceptibility For Mycobacterium tuberculosis within Families. Pediatric Infectious Disease Journal, 2012, 31, 783-785.	2.0	3
103	Epidemiology and management of childhood multidrug-resistant tuberculosis. Clinical Practice (London, England), 2012, 9, 701-713.	0.1	1
104	Caring for Children with Drug-Resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 953-964.	5.6	63
105	Management of children exposed to multidrug-resistant Mycobacterium tuberculosis. Lancet Infectious Diseases, The, 2012, 12, 469-479.	9.1	48
106	Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2012, 12, 449-456.	9.1	164
107	Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. South African Medical Journal, 2012, 102, 363.	0.6	56
108	Drug-Resistant Tuberculosis Transmission and Resistance Amplification within Families. Emerging Infectious Diseases, 2012, 18, 1342-5.	4.3	11

#	Article	IF	Citations
109	Commentary: minimizing the risk of non-vertical, non-sexual HIV infection in children â€“ beyond mother to child transmission. Journal of the International AIDS Society, 2012, 15, 17377.	3.0	3
110	Paediatric use of second-line anti-tuberculosis agents: A review. Tuberculosis, 2012, 92, 9-17.	1.9	56
111	Chapter 4: Isoniazid Pharmacokinetics and Efficacy in Adults and Children. Progress in Respiratory Research, 2011, , 25-31.	0.1	1
112	PYRAZINAMIDE PLASMA CONCENTRATIONS IN YOUNG CHILDREN WITH TUBERCULOSIS. Pediatric Infectious Disease Journal, 2011, 30, 262-265.	2.0	18
113	Induced sputum microbiology in confirming pulmonary tuberculosis in children [Editorial]. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1139-1139.	1.2	3
114	Drug-resistant Tuberculosis. Pediatric Infectious Disease Journal, 2011, 30, 501-505.	2.0	46
115	Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians. Paediatric Respiratory Reviews, 2011, 12, 31-38.	1.8	75
116	Opportunities for chemoprophylaxis in children with culture-confirmed tuberculosis. Annals of Tropical Paediatrics, 2011, 31, 301-310.	1.0	35
117	A randomized controlled trial of intermittent compared with daily cotrimoxazole preventive therapy in HIV-infected children. Aids, 2010, 24, 2225-2232.	2.2	7
118	Tuberculosis at extremes of age. Respirology, 2010, 15, 747-763.	2.3	123
119	Childhood Tuberculosis: An Emerging and Previously Neglected Problem. Infectious Disease Clinics of North America, 2010, 24, 727-749.	5.1	88
120	Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet, The, 2010, 375, 1830-1843.	13.7	866
121	UNSUSPECTED FATAL DRUG-RESISTANT TUBERCULOSIS IN A CLOSELY MONITORED CHILD: A PLEA FOR IMPROVED SOURCE-CASE TRACING AND DRUG SUSCEPTIBILITY TESTING. The Southern African Journal of Epidemiology & Infection: Official Journal of the Sexually Transmitted Diseases, Infectious Diseases and Epidemiological Societies of Southern Africa, 2010, 25, 30-32.	0.2	0
122	Intrathoracic tuberculosis in childrenThe most common clinical presentations. , 2009, , 361-363.		0
123	Isoniazid Plasma Concentrations in a Cohort of South African Children with Tuberculosis: Implications for International Pediatric Dosing Guidelines. Clinical Infectious Diseases, 2009, 48, 1547-1553.	5.8	125
124	Management algorithms for paediatric tuberculosis. , 2009, , 323-331.		0
125	Pediatric TB: issues related to current and future treatment options. Future Microbiology, 2009, 4, 661-675.	2.0	12
126	Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. BMC Medicine, 2009, 7, 19.	5.5	73

#	Article	IF	Citations
127	Radiology services for children in HIV- and TB-endemic regions: scope for greater collaboration between radiologists and clinicians caring for children. Pediatric Radiology, 2009, 39, 541-544.	2.0	1
128	A rapid method for detection of five known mutations associated with aminoglycoside-induced deafness. BMC Medical Genetics, 2009, 10, 2.	2.1	39
129	Multidrug-resistant tuberculosis in children. , 2009, , 532-538.		3
130	Tuberculosis drug therapy in children. , 2009, , 627-637.		1
131	Overview of extrapulmonary tuberculosis in adults and children. , 2009, , 377-390.		12
132	Preface. Clinics in Chest Medicine, 2009, 30, xiii-xviii.	2.1	5
133	Multidrug- and Extensively Drug-resistant Tuberculosis in Africa and South America: Epidemiology, Diagnosis and Management in Adults and Children. Clinics in Chest Medicine, 2009, 30, 667-683.	2.1	50
134	LONG-TERM LINEZOLID TREATMENT IN A YOUNG CHILD WITH EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS. Pediatric Infectious Disease Journal, 2009, 28, 748-750.	2.0	45
135	Surveillance of Antituberculosis Drug Resistance Among Children From the Western Cape Province of South Africaâ€"An Upward Trend. American Journal of Public Health, 2009, 99, 1486-1490.	2.7	71
136	Aminoglycoside-induced hearing loss: South Africans at risk. South African Medical Journal, 2009, 99, 440-1.	0.6	14
137	Clinical presentation and outcome of Tuberculosis in Human Immunodeficiency Virus infected children on anti-retroviral therapy. BMC Pediatrics, 2008, 8, 1.	1.7	147
138	Symptom-Based Screening of Child Tuberculosis Contacts: Improved Feasibility in Resource-Limited Settings. Pediatrics, 2008, 121, e1646-e1652.	2.1	67
139	Absence of an Association Between Mycobacterium tuberculosis Genotype and Clinical Features in Children With Tuberculous Meningitis. Pediatric Infectious Disease Journal, 2007, 26, 13-18.	2.0	21
140	Nosocomial infections in HIV-infected and HIV-uninfected children hospitalised for tuberculosis. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2007, 49, 14-14e.	0.6	1
141	Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ: British Medical Journal, 2007, 334, 136.	2.3	199
142	Failure of Chemoprophylaxis With Standard Antituberculosis Agents in Child Contacts of Multidrug-Resistant Tuberculosis Cases. Pediatric Infectious Disease Journal, 2007, 26, 1142-1146.	2.0	49
143	The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine, 2007, 25, 14-18.	3.8	220
144	Old and new drugs for the treatment of tuberculosis in children. Paediatric Respiratory Reviews, 2007, 8, 134-141.	1.8	37

#	Article	IF	Citations
145	Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases. BMC Infectious Diseases, 2007, 7, 140.	2.9	120
146	Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children. European Journal of Clinical Microbiology and Infectious Diseases, 2007, 26, 203-205.	2.9	48
147	Drug-resistant tuberculosis in children. South African Medical Journal, 2007, 97, 995-7.	0.6	12
148	Antimicrobial resistance in tuberculosis: an international perspective. Expert Review of Anti-Infective Therapy, 2006, 4, 759-766.	4.4	19
149	A Refined Symptom-Based Approach to Diagnose Pulmonary Tuberculosis in Children. Pediatrics, 2006, 118, e1350-e1359.	2.1	235
150	Tuberculous Lymphadenitis as a Cause of Persistent Cervical Lymphadenopathy in Children From a Tuberculosis-Endemic Area. Pediatric Infectious Disease Journal, 2006, 25, 142-146.	2.0	101
151	Radiographic Signs and Symptoms in Children Treated for Tuberculosis. Pediatric Infectious Disease Journal, 2006, 25, 237-240.	2.0	50
152	The Impact of a Change in Bacille Calmette-Gu??rin Vaccine Policy on Tuberculosis Incidence in Children in Cape Town, South Africa. Pediatric Infectious Disease Journal, 2006, 25, 1167-1172.	2.0	22
153	Comparison of Diagnostic Criteria of Tuberculous Meningitis in Human Immunodeficiency Virus-Infected and Uninfected Children. Pediatric Infectious Disease Journal, 2006, 25, 65-69.	2.0	87
154	A critical look at the diagnostic value of culture-confirmation in childhood tuberculosis. Journal of Infection, 2006, 53, 364-369.	3.3	21
155	Beijing and Haarlem Genotypes Are Overrepresented among Children with Drug-Resistant Tuberculosis in the Western Cape Province of South Africa. Journal of Clinical Microbiology, 2006, 44, 3539-3543.	3.9	77
156	Childhood Pulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1078-1090.	5.6	326
157	Childhood drugâ€resistant tuberculosis in the Western Cape Province of South Africa. Acta Paediatrica, International Journal of Paediatrics, 2006, 95, 523-528.	1.5	1
158	Childhood drug-resistant tuberculosis in the Western Cape Province of South Africa. Acta Paediatrica, International Journal of Paediatrics, 2006, 95, 523-528.	1.5	58
159	Recurrent Culture-Confirmed Tuberculosis in Human Immunodeficiency Virus-Infected Children. Pediatric Infectious Disease Journal, 2005, 24, 685-691.	2.0	64
160	Outcome of HIV infected children with culture confirmed tuberculosis. Archives of Disease in Childhood, 2005, 90, 1171-1174.	1.9	90
161	Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Archives of Disease in Childhood, 2005, 90, 614-618.	1.9	141
162	Clinical features and outcome in children admitted to a TB hospital in the Western Cape--the influence of HIV infection and drug resistance. South African Medical Journal, 2005, 95, 602-6.	0.6	31

#	Article	IF	Citations
163	A proposed radiological classification of childhood intra-thoracic tuberculosis. Pediatric Radiology, 2004, 34, 886-894.	2.0	163
164	Human immunodeficiency virus infection and child sexual abuse. South African Medical Journal, 2004, 94, 782-5.	0.6	3
165	Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome. Archives of Disease in Childhood, 2003, 88, 1106-1111.	1.9	94
166	Human immunodeficiency virus infection in children hospitalised with tuberculosis. Annals of Tropical Paediatrics, 2002, 22, 115-123.	1.0	22
167	Evaluation of Young Children in Contact With Adult Multidrug-Resistant Pulmonary Tuberculosis: A 30-Month Follow-up. Pediatrics, 2002, 109, 765-771.	2.1	179
168	Transmission of multidrug-resistant tuberculosis. Pediatric Infectious Disease Journal, 2000, 19, 695-700.	2.0	54
169	Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal, 2000, 19, 405-410.	2.0	64
170	HIV transmission between two siblings in Africa. Aids, 2000, 14, 896.	2.2	9
171	Evaluation of young children in household contact with adult multidrug-resistant pulmonary tuberculosis cases. Pediatric Infectious Disease Journal, 1999, 18, 494-500.	2.0	41
172	Management of children with tuberculosis admitted to a pediatric intensive care unit. Pediatric Infectious Disease Journal, 1998, 17, 403-407.	2.0	12
173	Culture-positive tuberculosis in human immunodeficiency virus type 1-infected children. Pediatric Infectious Disease Journal, 1998, 17, 599-604.	2.0	42
174	Challenges in childhood tuberculosis. , 0, , 234-262.		2